Registro:

Referencias:

• Hepatitis B vaccination - United States, 1982-2002 (2002) MMWR Morb Mortal Wkly Rep, 51, pp. 549-563
• Incidence of acute hepatitis B - United States, 1990-2002 (2004) MMWR Morb Mortal Wkly Rep, 52 (51-52), pp. 1252-1254. , 2 Jan
• Kubba, A.K., Taylor, P., Graneek, B., Strobel, S., Non-responders to hepatitis B vaccination: A review (2003) Commun Dis Public Health, 6 (2), pp. 106-112
• Lewis, D.J., Eiden, J.E., Goilav, C., Langenberg, A.G., Suggett, F., Griffin, G.E., Rapid and frequent induction of protective immunity exceeding UK, recommendations for healthcare settings by MF59-adjuvated hepatitis B vaccine (2003) Commun Dis Public Health, 6 (4), pp. 320-324
• Evans, T.G., Hasan, M., Galibert, L., Caron, D., The use of Flt3 ligand as an adjuvant for hepatitis B vaccination of healthy adults (2002) Vaccine, 21 (3-4), pp. 322-329
• Jacques, P., Moens, G., Desombere, I., Dewijngaert, J., Leroux-Roels, G., Wettendorff, M., The immunogenicity and reactogenicity profile of a candidate hepatitis B, vaccine in an adult vaccine non-responder population (2002) Vaccine, 20 (31-32), pp. 3644-3649
• Davis, H.L., Weeratna, R., Waldschmidt, T.J., Tygrett, L., Schorr, J., Krieg, A.M., Weeranta, R., CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen (1998) J Immunol, 160, pp. 870-876
• Halperin, S.A., Van Nest, G., Smith, B., Abtahi, S., Whiley, H., Eiden, J.J., A phase I study of the safety and immunogenicity of recombinant hepatitis B surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide adjuvant (2003) Vaccine, 21, pp. 2461-2467
• Krieg, A.M., CpG motifs in bacterial DNA and their immune effects (2002) Annu Rev Immunol, 20, pp. 709-760
• Elías, F., Fló, J., Lopez, R.A., Zorzopulos, J., Montaner, A., Rodriguez, J.M., Strong cytosine-guanosine-independent immunostimulation in humans and other primates by synthetic oligodeoxynucleotides with PyNTTTTGT motifs (2003) J Immunol, 171, pp. 3697-3704
• Klinman, D.M., Immunotherapeutic uses of CpG oligonucleotides (2004) Nature Rev Immunol, 4, pp. 249-258
• Lipford, G.B., Bauer, M., Blank, C., Reiter, R., Wagner, H., Heeg, K., CpG-containing synthetic oligodeoxynucleotides promote B and cytotoxic T cell responses to protein antigen: A new class of vaccine adjuvants (1997) Eur J Immunol, 27, p. 2340
• Chu, R.S., Targoni, O.S., Krieg, A.M., Lehman, P.V., Harding, C.V., CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity (1997) J Exp Med, 186, p. 1623
• Moldovenu, G.J., Love-Homan, L., Huang, W.Q., Krieg, A.M., CpG DNA, a novel immune enhancer for systemic and mucosal immunization with influenza virus (1998) Vaccine, 16, p. 1216
• Weeratna, R., McCluskie, M.J., Yu, X., Davis, H.L., CpG DNA induces stronger immune responses with less toxicity than other adjuvants (2000) Vaccine, 18, p. 1755
• Rankin, R., Pontarollo, R., Ioannou, X., Krieg, A.M., Hecker, R., Babiuk, L.A., CpG motif identification for veterinary and laboratory species demonstrates that sequence recognition is highly conserved (2001) Antisense Nucleic Acid Drug Dev, 11 (5), pp. 333-340
• Saoudi, A., Kuhn, J., Huygen, K., De Kozak, Y., Velu, T., Goldman, M., TH2 activated cells prevent experimental autoimmune uveoretinitis, a TH1-dependent autoimmune disease (1993) Eur J Immunol, 23, pp. 3096-3103
• Gracie, J.A., Bradley, J.A., Interleukin-12 induces interferon-gamma-dependent switching of IgG alloantibody subclass (1996) Eur J Immunol, 26, pp. 1217-1221
• Bomford, R., Will adjuvants be needed for vaccines of the future? (1998) Dev Biol Stand, 92, pp. 13-17
• Gupta, R.K., Aluminum compounds as vaccine adjuvants (1998) Adv Drug Deliv Rev, 32, pp. 155-172
• Chisari, F.V., Hepatitis B virus immunopathogenesis (1995) Annu Rev Immunol, 13, pp. 29-60
• Bertoletti, A., D'Elios, M.M., Boni, C., De Carli, M., Zignego, A.L., Durazzo, M., Different cytokine profiles of intraphepatic T cells in chronic hepatitis B and hepatitis C virus infections (1997) Gastroenterology, 112 (1), pp. 193-199
• Guidotti, L.G., Ishikawa, T., Hobbs, M.V., Matzke, B., Schreiber, R., Chisari, F.V., Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes (1996) Immunity, 4 (1), pp. 25-36
• Jung, M.C., Hartmann, B., Gerlach, J.T., Diepolder, H., Gruber, R., Schraut, W., Virus-specific lymphokine production differs quantitatively but not qualitatively in acute and chronic hepatitis B infection (1999) Virology, 261 (2), pp. 165-172
• Penna, A., Del Prete, G., Cavalli, A., Bertoletti, A., D'Elios, M.M., Sorrentino, R., Predominant T-helper 1 cytokine profile of hepatitis B virus nucleocapsid-specific T cells in acute self-limited hepatitis B (1997) Hepatology, 25 (4), pp. 1022-1027
• McGeady, S.J., Immunocompetence and allergy (2004) Pediatrics, 113 (4 SUPPL.), pp. 1107-1113
• Chung, K.F., Individual cytokines contributing to asthma pathophysiology: Valid targets for asthma therapy? (2004) Curr Opin Invest Drugs, 4 (11), pp. 1320-1326
• Ronnblom, L., Eloranta, M.L., Alm, G.V., Role of natural interferon-alpha producing cells (plasmacytoid dendritic cells) in autoimmunity (2003) Autoimmunity, 36 (8), pp. 463-472
• Conrad, B., Potential mechanisms of interferon-alpha induced autoimmunity (2003) Autoimmunity, 36 (8), pp. 519-523

Citas:

---------- APA ----------

---------- CHICAGO ----------

---------- MLA ----------

---------- VANCOUVER ----------